Ara-290
Typical Dosing Protocols (Research/Compounded Use Only) – Ara-290 (Cibinetide)
Common protocol: 2–4 mg subcutaneously once daily for 28 consecutive days (most clinical trials used 4 mg daily). Some protocols begin with 2 mg daily for the first week then increase to 4 mg.
Other reported ranges:
Standard research/wellness: 2–4 mg daily
Higher: Up to 6–8 mg daily in some exploratory settings (less common)
Frequency: Once daily (often in the morning); cycles typically 28 days (4 weeks), with some extending to 6–12 weeks depending on goals. Repeat cycles after a break are sometimes used.
Reconstitution example (for a typical 16 mg vial, common research size): Add 2 mL bacteriostatic water(yielding 8 mg/mL).
2 mg = 0.25 mL (25 units on U-100 insulin syringe)
4 mg = 0.5 mL (50 units)
Administration: Subcutaneous injection (abdomen or thigh). Rotate injection sites.
Dosing is highly individualized based on goals (neuropathy support, inflammation, tissue repair) and response—consult a qualified healthcare provider experienced with peptides for personalized guidance. This is for informational purposes only.
